Breaking News
Challenges and Concerns for Nio Analysts Slash Price Targets
Nio's stock took a hit as analysts slashed their price targets following the company's fourth-quarter financial results. JPMorgan's Nick Lai...
Applied Therapeutics Reports Disappointing Q4 Financial Results
Applied Therapeutics (NASDAQ: APLT) unveiled its Q4 financial results on March 6, 2024, at 07:00 AM, revealing some important details:...
Consistent Perform Ratings for ChargePoint Holdings Inc despite Recent Developments
Analyst Colin Rusch from Oppenheimer has decided to keep his Perform rating on ChargePoint Holdings Inc (NYSE: CHPT) despite recent...
Analyst Maintains Outperform Rating and Raises Price Target for Cannae Holdings
Analyst Ian Zaffino of Oppenheimer continues to show confidence in Cannae Holdings (NYSE: CNNE) by maintaining an Outperform rating and...
Title Precision BioSciences Partner Receives Approval to Expand Clinical Trial for ARCUS Gene Editing Program Targeting OTC Deficiency
Precision BioSciences has recently revealed that iECURE, its partner, has been granted approval by the UK's Medicines and Healthcare products...
Farewell to Andres Lopez A Legacy of Leadership and Innovation
Andres Lopez, the esteemed Chief Executive Officer of O-I Glass, Inc., will be bidding farewell on May 15, 2024, after...
Groundbreaking Clinical Study Shows Effectiveness of AVIM Therapy in Hypertensive Pacemaker Patients
Orchestra BioMed recently completed a groundbreaking clinical study on March 6, 2024, to assess the effectiveness of AVIM therapy in...
BTIG Analyst Gray Powell Optimistic about HashiCorps Future Growth
BTIG analyst Gray Powell is bullish on HashiCorp (HCP) and has increased the price target to $27 from $25. This...
Harvard Bioscience Inc Unveils CuttingEdge Product Advancements for Research at SOT Conference
Harvard Bioscience, Inc. is set to unveil its cutting-edge product advancements at the upcoming Society of Toxicology (SOT) conference in...
Analyst Reaffirms Sell Rating on Stellus Capital Investment with Lower Price Target
On March 6, 2024, Bryce Rowe, an analyst at B. Riley Securities, reaffirmed his Sell rating on Stellus Capital Investment...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
Synopsys Shares Plummet Amid Fraud Allegations and Disappointing Earnings
